delirium. Delirium due to known physiological condition
Conditions
Interventions
Intervention 1: In the group receiving dexmedetomidine manufactured by Exir pharmaceutical company, the drug is administered intravenously with a starting dose of 0.5 µg/kg per hour. To achieve the ef
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients who are diagnosed with delirium based on DSM5 criteria. Patients who have not received non-pharmacological treatments to control symptoms. 5=ICDSC ? RASS=+1 Not being intubated or extubated for more than 24 hours Hospitalization in ICU for non-surgical reasons
Exclusion criteria
Exclusion criteria: Patients who receive drugs other than dexmedetomidine or haloperidol for the treatment of delirium (such as other antipsychotics and midazolam) Receiving dexmedetomidine or haloperidol within 72 hours before entering the study Patients with a history of drug sensitivity to dexmedetomidine or haloperidol. Patients with a history of long QTc (<500 ms) Patients with dementia, Parkinson's, malignant neuroleptic syndrome, patients with a history of major psychiatric disorders such as bipolar and schizophrenia, addiction to various drugs and stimulants. Women during breastfeeding and pregnancy Unwillingness of the patient or family to participate in the study Severe forms of vision and hearing
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean score of ICDSC questionnaire. Timepoint: Intensive care Delirium Screening checklist (ICDSC) will be evaluated for daily delirium evaluation for up to 3 days. Method of measurement: Intensive care Delirium Screening checklist (ICDSC).;Mean SCORE OF RASS QUESTIONNAIRE. Timepoint: After the intervention, every hour to 6 hours, then every 1 hour to 3 days. Method of measurement: Richmond Agitation Sedation Scale (RASS). | — |
Secondary
| Measure | Time frame |
|---|---|
| ICDSC and RASS questionnaires for patients at specified intervals and results were obtained. Timepoint: Every one hour to six hours after starting the medicine and then continue every six hours to seventy two hours. Method of measurement: Richmond Agitation Sedation Scale (RASS) scoring system and also Intensive care Delirium Screening checklist (ICDSC).;Delirium intensity. Timepoint: From the time of intervention (drug prescription) daily for 3 days. Method of measurement: Patient's clinical status. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAhmadReza Aghabozorgi
Esfahan University of Medical Sciences
Outcome results
None listed